Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

Current Atherosclerosis Reports

Volumn 10, Issue 1, 2008, Pages 25-32

  Brinton, Eliot A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADJUVANT THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; DYSPEPSIA; GASTROINTESTINAL TOXICITY; HUMAN; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG EMBOLISM; MONOTHERAPY; MYOPATHY; NAUSEA; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLOFIBRIC ACID; DIABETIC ANGIOPATHIES; DRUG THERAPY, COMBINATION; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROCETOFEN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHABDOMYOLYSIS; RISK ASSESSMENT; TRIGLYCERIDES;

EID: 40749126432     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0005-3     Document Type: Review

References (70)

1. Grundy SM, Cleeman JI, Merz CN, et al.: A summary of implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004, 24:1329-1330.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
3. Stone N, Blum C: Management of Lipids in Clinical Practice, edn 6. Caddo, OK: Professional Communications Inc.; 2006.
4. Chinetti G, Lestavel S, Bocher V, et al.: PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001, 7:53-58.
5. Brinton EA, Eisenberg S, Breslow JL: Increased apo A-I and apo A-II fractional catabolic rate in patients with low high density lipoprotein-cholesterol levels with or without hypertriglyceridemia. J Clin Invest 1991, 87:536-544.
6. Duval C, Chinetti G, Trottein F, et al.: The role of PPARs in atherosclerosis. Trends Mol Med 2002, 8:422-430.
7. Lee CH, Olson P, Evans RM: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 2003, 144:2201-2207.
8. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
9. Keech A, Simes RJ, Barter P, et al.: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
10. Vakkilainen J, Steiner G, Ansquer JC, et al.: Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733-1737.
11. Filippatos TD, Gazi IF, Liberopoulos EN, et al.: The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007, 193:428-437.
12. Farnier M, Bonnefous F, Debbas N, Irvine A: Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994, 154:441-449.
13. Bredie SJ, Westerveld HT, Knipscheer HC, et al.: Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia. Neth J Med 1996, 49:59-67.
14. Balogh Z, Seres I, Harangi M, et al.: Gemfibrozil increases paraoxonase activity in type 2 diabetic patients. A new hypothesis of the beneficial action of fibrates? Diabetes Metab 2001, 27(5 Pt 1):604-610.
15. Grundy SM, Vega GL, Yuan Z, et al.: Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005, 95:462-468.
16. Athyros VG, Papageorgiou AA, Athyrou VV, et al.: Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002, 25:1198-1202.
17. Derosa G, Cicero AE, Bertone G, et al.: Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther 2004, 26:1599-1607.
18. Robins SJ, Collins D, Wittes JT, et al.: Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
19. Otvos JD, Collins D, Freedman DS, et al.: Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
20. Rosenson RS, Wolff DA, Huskin AL, et al.: Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007, 30:1945-1951.
21. Koh KK, Han SH, Quon MJ, et al.: Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia. Diabetes Care 2005, 28:1419-1424.
22. Staels B, Koenig W, Habib A, et al.: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
23. Melenovsky V, Malik J, Wichterle D, et al.: Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J 2002, 144(4):E6.
24. Malik J, Melenovsky V, Wichterle D, et al.: Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial - FAT). Cardiovasc Res 2001, 52:290-298.
25. Marx N, Sukhova GK, Collins T, et al.: PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999, 99:3125-3131.
26. Neve BP, Corseaux D, Chinetti G, et al.: PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001, 103:207-212.
27. Marx N, Mackman N, Schonbeck U, et al.: PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001, 103:213-219.
28. Marx N, Kehrle B, Kohlhammer K, et al.: PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002, 90:703-710
29. Xu X, Otsuki M, Saito H, et al.: PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endotheial cells. Endocrinology 2001, 142:3332-3339.
30. Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987, 317:1237-1245.
31. Tenkanen L, Mänttäri M, Manninen V: Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995, 92:1779-1785.
32. Manninen V, Tenkanen L, Koskinen P, et al.: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study. Implications for treatment. Circulation 1992, 85:37-45.
33. Robins SJ, Bloomfield HE: Fibric acid derivatives in cardiovascular disease prevention: results from the large clinical trials. Curr Opin Lipidol 2006, 17:431-439.
34. Rubins HB, Robins SJ, Collins D, et al.: Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med 2002, 162:2597-2604.
35. Barter PJ, Rye KA: Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol 2007, In press.
36. Hodis HN, Mack WJ, LaBree L, et al.: The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128:262-269.
37. Frick MH, Syvanne M, Nieminen MS, et al.: Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997, 96:2137-2143.
38. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001, 357:905-910.
39. Haffner SM, Stern MP, Gruber MK, et al.: Potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 1990, 10:727-731.
40. Pedrinelli R, Giampietro O, Carmassi F, et al.: Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994, 344:14-18.
41. Ansquer JC, Foucher C, Rattier S, et al.: Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am J Kidney Dis 2005, 45:485-493.
42. Buse JB, Bigger JT, Byington RP, et al.: Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99(12A):21i-33i.
43. Ginsberg HN, Bonds DE, Lovato LC, et al.: Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007, 99(12A):56i-67i.
44. Meyers CD, McCarren M, Wong ND, et al.: Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial). Am J Cardiol 2006, 98: 63-65.
45. Ashen MD, Blumenthal RS: Clinical practice. Low HDL cholesterol levels. N Engl J Med 2005, 353:1252-1260.
46. Roberts WC: Safety of fenofibrate - US and worldwide experience. Cardiology 1989, 76:169-179.
47. Knopp RH: Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511.
48. Davidson MH, Armani A, McKenney JM, Jacobson TA: Safety considerations with fibrate therapy. Am J Cardiol 2007, 99(6A):3C-18C.
49. Hottelart C, El Esper N, Rose F, et al.: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron 2002, 92:536-541.
50. Levin A, Duncan L, Djurdjev O, et al.: A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol 2000, 53:140-146.
51. Deighan CJ, Caslake MJ, McConnell M, et al.: Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. J Am Soc Nephrol 2001, 12:341-348.
52. Dalton RN, Ansquer JC. Presented at American Society of Nephrology Meeting. Philadelphia, 2005.
53. Lipscombe J, Lewis GF, Cattran D, Bargman JM: Deterioration in renal function associated with fibrate therapy. Clin Nephrol 2001, 55:39-44.
54. Tonelli M, Collins D, Robins S, et al.: Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int 2004, 66:1123-1130.
55. Kasiske B, Cosio FG, Beto J, et al.: Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004, 4(Suppl 7):13-53.
56. Westphal S, Dierkes J, Luley C: Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001, 358:39-40.
57. Bissonnette R, Treacy E, Rozen R, et al.: Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 2001, 155:455-462.
58. Keech T: Paper presented at American Heart Association Annual Scientific Sessions 2006. Chicago, 2006.
59. Graham DJ, Staffa JA, Shatin D, et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004, 292:2585-2590.
60. Alsheikh-Ali AA, Kuvin JT, Karas RH: Risk of adverse events with fibrates. Am J Cardiol 2004, 94:935-938.
61. Layne RD, Sehbai AS, Stark LJ: Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy. Ann Pharmacother 2004, 38:232-234.
62. Gaist D, Rodriguez LA, Huerta C, et al.: Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001, 12:565-569.
63. Jones PH, Davidson MH: Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005, 95:120-122.
64. Prueksaritanont T, Tang C, Qiu Y, et al.: Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002, 30:1280-1287.
65. Prueksaritanont T, Zhao JJ, Ma B, et al.: Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002, 301:1042-1051.
66. Martin PD, Dane AL, Schneck DW, Warwick MJ: An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003, 25:459-471.
67. Pan WJ, Gustavson LE, Achari R, et al.: Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 2000, 40:316-323.
68. Jacobson TA, Zimmerman FH: Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 2006, 8:35-41; quiz 2-3.
69. Grundy SM: The issue of statin safety: where do we stand? Circulation 2005, 111:3016-3019.
70. Grundy SM, Hansen B, Smith SC Jr, et al.: Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004, 109:551-556.